Bio-Techne Corporation
Financials
Valuation Metrics
Bio-Techne Corporation's Market Cap is $11.29B. At end of 2025 it was $9.15B. Ranked #878 of 3,111 in US market (top 28%), #275 of 1,445 on NASDAQ (top 19%), #40 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $11.29B | US#878/3,111 Sec#40/269 |
| Revenue | $1.21B | US#1,826/3,111 Sec#48/269 |
| Net Income | $110M | US#1,569/3,111 Sec#55/269 |
| Total Assets | $2.55B | US#1,920/3,111 Sec#51/269 |
| Net Assets | $2.09B | US#1,224/3,111 Sec#39/269 |
| Employees | 3,100 | US#987/3,111 Sec#22/269 |
| Value | ||
| P/E | 103.08x | US#2,058/3,111 Sec#66/269 |
| P/B | 5.42x | US#2,252/3,111 Sec#147/269 |
| PEG | 0.82x | US#738/3,111 Sec#28/269 |
| P/S | 9.33x | US#2,638/3,111 Sec#116/269 |
| EV/EBITDA | 44.09x | US#2,321/3,111 Sec#74/269 |
| FCF Yield | 2.39% | US#1,886/3,111 Sec#67/269 |
| Profitability | ||
| ROE | 5.25% | US#1,837/3,111 Sec#65/269 |
| ROA | 4.30% | US#1,138/3,111 Sec#57/269 |
| Op. Margin | 12.70% | US#1,407/3,111 Sec#58/269 |
| Revenue Growth | -1.51% | US#2,360/3,111 Sec#130/269 |
| Earnings Growth | 126.04% | US#286/3,111 Sec#12/269 |
| Financial Health | ||
| Debt Ratio | 22.31% | US#243/3,111 Sec#83/269 |
| Total Debt | $290M | US#2,077/3,111 Sec#78/269 |
| FCF | $270M | US#1,202/3,111 Sec#39/269 |
| Cash | $210M | US#1,692/3,111 Sec#111/269 |
| Current Ratio | 4.49x | US#537/3,111 Sec#161/269 |
| Net Debt/EBITDA | 0.31x | US#733/3,111 Sec#42/269 |
| Dividend | ||
| Div. Yield | 0.44% | US#1,544/3,111 Sec#25/269 |
| Div. Growth | 0.06% | US#1,243/3,111 Sec#22/269 |
| Performance | ||
| 1Y Return | 31.98% | US#1,103/3,111 Sec#144/269 |
| 1M Return | 1.85% | US#1,325/3,111 Sec#84/269 |
| From 52W High | -0.30% | US#20/3,111 Sec#5/269 |
| 1Y MDD | -39.26% | US#1,913/3,111 Sec#141/269 |
| Trading | ||
| Volume | 3,264,664 shares | US#489/3,111 Sec#36/269 |
| Trading Value | $236M | US#374/3,111 Sec#19/269 |
| Per Share | ||
| EPS | $0.52 | US#1,827/3,111 Sec#63/269 |
| BPS | $12.90 | US#1,608/3,111 Sec#52/269 |
Company Info
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.